Gilead Sciences
lopinavir ritonavir ![]() Lopinavir Ritonavir, supplied by Gilead Sciences, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/lopinavir ritonavir/product/Gilead Sciences Average 86 stars, based on 1 article reviews
lopinavir ritonavir - by Bioz Stars,
2025-02
86/100 stars
|
Buy from Supplier |
Abbott Laboratories
lopinavir ritonavir ![]() Lopinavir Ritonavir, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/lopinavir ritonavir/product/Abbott Laboratories Average 86 stars, based on 1 article reviews
lopinavir ritonavir - by Bioz Stars,
2025-02
86/100 stars
|
Buy from Supplier |
AbbVie Inc
lopinavir ritonavir ![]() Lopinavir Ritonavir, supplied by AbbVie Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/lopinavir ritonavir/product/AbbVie Inc Average 86 stars, based on 1 article reviews
lopinavir ritonavir - by Bioz Stars,
2025-02
86/100 stars
|
Buy from Supplier |
Porsolt
lopinavir ritonavir ![]() Lopinavir Ritonavir, supplied by Porsolt, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/lopinavir ritonavir/product/Porsolt Average 86 stars, based on 1 article reviews
lopinavir ritonavir - by Bioz Stars,
2025-02
86/100 stars
|
Buy from Supplier |
Image Search Results

Journal: Advances in Therapy
Article Title: Perspectives on the Early Quality of Evidence Guiding the Therapeutic Management of SARS-CoV-2: A Systematic Literature Review
doi: 10.1007/s12325-020-01460-5
Figure Lengend Snippet: Early clinical evidence for the treatment of SARS-CoV-2
Article Snippet: WHO, May, 2020 , Chloroquine/hydroxychloroquine,
Techniques: Infection

Journal: Advances in Therapy
Article Title: Perspectives on the Early Quality of Evidence Guiding the Therapeutic Management of SARS-CoV-2: A Systematic Literature Review
doi: 10.1007/s12325-020-01460-5
Figure Lengend Snippet: Treatment recommendation from different guidelines and an update on COVID-19 vaccines
Article Snippet: WHO, May, 2020 , Chloroquine/hydroxychloroquine,
Techniques:

Journal: Antiviral Research
Article Title: Brain Injury Caused by HIV Protease Inhibitors: role of Lipodystrophy and Insulin Resistance
doi: 10.1016/j.antiviral.2012.04.010
Figure Lengend Snippet: Metabolic consequences of chronic L/R Male C57BL/6 mice were treated daily with vehicle or lopinavir/ritonavir (150/37.5 mg/kg body weight) for 28 days, after which mice were evaluated for metabolic changes reflecting lipodystrophy, insulin resistance, and hyperlipidemia as described in Methods. Values are mean and S.E.M. data collected from 9–20 animals over 2 separate cohorts.
Article Snippet: Since both the Stone T-maze and
Techniques:

Journal: Antiviral Research
Article Title: Brain Injury Caused by HIV Protease Inhibitors: role of Lipodystrophy and Insulin Resistance
doi: 10.1016/j.antiviral.2012.04.010
Figure Lengend Snippet: Male C57BL/6 mice were treated daily with vehicle or lopinavir/ritonavir (150/37.5 mg/kg body weight) for 28 days, after which mice were evaluated behaviorally as described in Methods. Experiments were conducted in 9–20 animals per group over 2 separate cohorts. (A) Effects of lopinavir/ritonavir on cognitive performance in the Stone T-maze. Data show the number of errors committed over 15 trials of maze training and are means ± S.E.M. of average errors accrued over 3-trial blocks. Data were analyzed by 2-way ANOVA, and the insert depicts the significant main effects of trial number, treatment group, and the significant interaction between trial and treatment. *and ** indicate significant (p<0.05, p<0.01, respectively) increases in errors made by lopinavir/ritonavir-treated mice in trial blocks 4–6 and 10–12. (B) Effects of lopinavir/ritonavir on behavioral despair in Porsolt forced swim test. Data depict time spent in swimming/escape behavior, and were analyzed by 2-tailed, unpaired t-tests. * indicates the significant (p<0.05) decrease in swim time in lopinavir/ritonavir-treated mice as compared to vehicle-treated mice. (C) Effects of lopinavir/ritonavir on motor performance in the Rotarod test. Data depict the time mice were able to remain on the accelerating rotarod, and are mean ± S.E.M. of average time over 3 trails.
Article Snippet: Since both the Stone T-maze and
Techniques:

Journal: Antiviral Research
Article Title: Brain Injury Caused by HIV Protease Inhibitors: role of Lipodystrophy and Insulin Resistance
doi: 10.1016/j.antiviral.2012.04.010
Figure Lengend Snippet: Scatter plots show the statistically significant linear relationship between errors in acquisition trail block 4–6 (errors in ACQ4–6) and (A) fat mass, (B) serum leptin, and (C) serum adiponectin in vehicle- and lopinavir/ritonavir-treated mice. Each point represents an individual subject, and closed circles depict vehicle-treated mice while open circles depict lopinavir/ritonavir-treated mice.
Article Snippet: Since both the Stone T-maze and
Techniques: Blocking Assay

Journal: Antiviral Research
Article Title: Brain Injury Caused by HIV Protease Inhibitors: role of Lipodystrophy and Insulin Resistance
doi: 10.1016/j.antiviral.2012.04.010
Figure Lengend Snippet: Scatter plots show the statistically significant linear relationship between errors in acquisition trail block 4–6 (errors in ACQ4–6) and (A) fasting insulin, (B) circulating NEFA 60 minutes following oral glucose administration (Post-Glu NEFA), and (C) fasting triglycerides in vehicle- and lopinavir/ritonavir-treated mice. Each point represents an individual subject, and closed circles depict vehicle-treated mice while open circles depict lopinavir/ritonavir-treated mice.
Article Snippet: Since both the Stone T-maze and
Techniques: Blocking Assay

Journal: Antiviral Research
Article Title: Brain Injury Caused by HIV Protease Inhibitors: role of Lipodystrophy and Insulin Resistance
doi: 10.1016/j.antiviral.2012.04.010
Figure Lengend Snippet: Male C57BL/6 mice were treated daily with vehicle or lopinavir/ritonavir (150/37.5 mg/kg body weight) for 28 days, after which markers of cerebrovascular integrity, synaptic density, and reactive gliosis were evaluated in tissue homogenates prepared from the frontal cortex as described in Methods. Data depict mean ± SEM expression in lopinavir/ritonavir-treated mice presented as % vehicle (100% line) on graph. Data were obtained from 9–20 mice/group, and were analyzed by 2-tailed, unpaired t-tests. (A) Expression of the tight junction proteins claudin-5, ZO-1, and occludin; and the matrix metalloproteinases MMP2 and MMP9. * and ** indicate significant (p < 0.05 and 0.01, respectively) changes in expression in lopinavir/ritonavir-treated mice as compared to vehicle. (B) Expression of the post-synaptic marker synapse associated protein 97 (SAP97), the pre-synaptic protein synapsin 1, and phosphorylated synapsin 1. * indicates significant (p < 0.05) the significant decrease in phosphorylated synapsin 1 expression in lopinavir/ritonavir-treated mice. (C) Expression of the glial markers glial fibrillary acidic protein (GFAP) and Iba-1. * indicates significant (p < 0.05) increases in GFAP and Iba-1 expression in lopinavir/ritonavir-treated mice.
Article Snippet: Since both the Stone T-maze and
Techniques: Expressing, Marker

Journal: Antiviral Research
Article Title: Brain Injury Caused by HIV Protease Inhibitors: role of Lipodystrophy and Insulin Resistance
doi: 10.1016/j.antiviral.2012.04.010
Figure Lengend Snippet: Male C57BL/6 mice were treated daily with vehicle or lopinavir/ritonavir (150/37.5 mg/kg body weight) for 28 days, and the effects of lopinavir/ritonavir the cytokines (A) TNFα, (B) IL-1β, (C) IL-6 and (D) the growth factor BDNF in cortex were evaluated by ELISA as described in Methods. Data are means and SEM, with 9–20 individual mice per group, and were analyzed by 2-tailed, unpaired t-tests. *, **, and *** indicate significant (p<0.05, p<0.01, and p<0.001, respectively) differences in expression in lopinavir/ritonavir-treated mice as compared to vehicle.
Article Snippet: Since both the Stone T-maze and
Techniques: Enzyme-linked Immunosorbent Assay, Expressing

Journal: Antiviral Research
Article Title: Brain Injury Caused by HIV Protease Inhibitors: role of Lipodystrophy and Insulin Resistance
doi: 10.1016/j.antiviral.2012.04.010
Figure Lengend Snippet: Western blot data from Hippocampus and Cerebellum Male C57BL/6 mice were treated daily with vehicle or lopinavir/ritonavir (150/37.5 mg/kg body weight) for 28 days, after which the expression of markers of brain injury in hippocampus and cerebellum were measured by Western blot as described in Methods.
Article Snippet: Since both the Stone T-maze and
Techniques: Western Blot, Expressing